- Previous Close
34.10 - Open
34.55 - Bid 34.45 x --
- Ask 34.60 x --
- Day's Range
34.20 - 34.85 - 52 Week Range
32.80 - 58.20 - Volume
239,720 - Avg. Volume
104,267 - Market Cap (intraday)
2.684B - Beta (5Y Monthly) 0.71
- PE Ratio (TTM)
27.46 - EPS (TTM)
1.26 - Earnings Date Mar 10, 2025 - Mar 14, 2025
- Forward Dividend & Yield 0.80 (2.08%)
- Ex-Dividend Date Jul 26, 2024
- 1y Target Est
--
Chunghwa Chemical Synthesis & Biotech Co., Ltd. engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (APIs) in Taiwan and the United States. It offers API products, which include immunosuppressant, oncology, anti-virus, immunomodulating agents, and other products, as well as peptide drugs. The company also develops bulk pharmaceutical products, such as anti-anxiety agents, antidiabetics, laxatives, antifungals, antihistamines, antiseptics, antiulcerants, cardiovascular drugs, skeletal, muscle relaxants, hypolipaemics, antineoplastic, antihyperlipedemias, and immunosuppressant products, as well as provides research and development, and contract manufacturing services to new drug developers and generic drug companies. The company was formerly known as China Chemical Synthesis Industry Co., Ltd. Chunghwa Chemical Synthesis & Biotech Co., Ltd. was founded in 1964 and is headquartered in New Taipei City, Taiwan.
www.ccsb.com.twRecent News: 1762.TW
View MorePerformance Overview: 1762.TW
Trailing total returns as of 12/27/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 1762.TW
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 1762.TW
View MoreValuation Measures
Market Cap
2.68B
Enterprise Value
3.50B
Trailing P/E
27.46
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.77
Price/Book (mrq)
0.80
Enterprise Value/Revenue
2.31
Enterprise Value/EBITDA
10.46
Financial Highlights
Profitability and Income Statement
Profit Margin
7.81%
Return on Assets (ttm)
1.04%
Return on Equity (ttm)
3.53%
Revenue (ttm)
1.51B
Net Income Avi to Common (ttm)
117.69M
Diluted EPS (ttm)
1.26
Balance Sheet and Cash Flow
Total Cash (mrq)
213.07M
Total Debt/Equity (mrq)
30.13%
Levered Free Cash Flow (ttm)
-253.52M